SCHEDULE: State Street Discloses 5.1% Stake in Emergent BioSolutions

State Street Corporation has reported a 5.1% beneficial ownership stake in Emergent BioSolutions Inc., holding 2,696,375 shares of common stock.

Summary

• State Street Corporation, a Massachusetts-based parent holding company, has filed a Schedule 13G indicating beneficial ownership in Emergent BioSolutions Inc.
• As of December 31, 2025, State Street Corporation beneficially owned 2,696,375 shares of Emergent BioSolutions Inc. common stock.
• This ownership represents 5.1% of the total class of securities.
• State Street Corporation holds shared voting power over 2,493,618 shares and shared dispositive power over 2,696,375 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Subsidiaries involved in the beneficial ownership include SSGA FUNDS MANAGEMENT, INC., STATE STREET GLOBAL ADVISORS EUROPE LIMITED, STATE STREET GLOBAL ADVISORS LIMITED, and STATE STREET GLOBAL ADVISORS TRUST COMPANY.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive. While a Schedule 13G is a factual disclosure of ownership, the reporting of a 5.1% stake by a major institutional investor like State Street Corporation can be seen as a positive signal of institutional interest in Emergent BioSolutions Inc.

Positives

• State Street Corporation, a significant institutional investor, has reported a 5.1% beneficial ownership stake in Emergent BioSolutions Inc., which can be interpreted as a signal of institutional confidence.

Negatives

• No negative information regarding the issuer's operational or financial performance is disclosed in this beneficial ownership report.

Risks

• No specific risks related to Emergent BioSolutions Inc.'s operations or financial health are detailed within this beneficial ownership filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Emergent BioSolutions Inc.'s future performance or outlook.

Industry Context

StockSavvy.ai notes that the disclosure of a significant institutional stake by a major asset manager like State Street Corporation in a biotechnology firm like Emergent BioSolutions Inc. is a common occurrence in the market, reflecting portfolio allocation decisions rather than specific industry-wide trends or competitive shifts.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder may influence investor perception and potentially increase confidence in the stock.

Key Dates

Keywords

Emergent BioSolutions, State Street Corporation, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Schedule 13G, Biotechnology, Pharmaceuticals